PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA ( …